Figure 1.

Effects of E2, the ERα-selective agonist, PPT, and the ERβ-selective agonist, DPN, on the migration of the DU-145 cells. (A) Cells, in the same culture plate in different wells, were wounded and then incubated in the absence (C, control) or presence of E2 (10 nM), ERα-selective agonist PPT (10 nM) or ERβ-selective agonist DPN (B) for 24 h at 37°C. (B) Cells were also untreated or pre-treated with the ERα-selective antagonist MPP (10 nM), ERβ-selective antagonist PHTPP (10 nM) or with both antagonists, MPP (10 nM) and PHTPP (10 nM) for 30 min. Incubation was continued in the presence of E2 (10 nM) for 24 h at 37°C. Wound healing assay was performed as described in the Materials and methods. The results are expressed in relation to the control (C=100%) and plotted (mean ± SEM) from four to five independent experiments, in duplicate (bar graphs). Images (×100 magnification) are representative of four to five independent experiments performed in duplicate. *P<0.05, significantly different from the control; ^#P<0.05, significantly different from the MPP + E2, PHTPP + E2, or MPP + PHTPP + E2 groups (determined using ANOVA and Tukey's post hoc test). E2, 17β-estradiol; ER, estrogen receptor; PPT, 4,4′,4”-(4-propyl- (1H)-pyrazole-1,3,5-triyl)trisphenol; DPN, 2,3-bis(4-hydroxyphenyl)-propionitrile; MPP, 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP, 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol.